TSLA
Tesla
-- 421.060 PLTR
Palantir
-- 80.550 NVDA
NVIDIA
-- 134.700 OXY
Occidental Petroleum
-- 47.130 AMD
Advanced Micro Devices
-- 119.210 
NEWS
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
AC Immune (NASDAQ: ACIU) announced positive interim results from its Phase 2 VacSYn trial of ACI-7104.056, an active immunotherapy for early Parkinson's disease.
The treatment showed significant efficacy, inducing anti-a-synuclein antibody levels 16-fold higherthan placebo after 3 immunizations, with a 100% patient response rate.
The trial reported positive safety data with only minor side effects including injection site reactions (49%) and headaches (18%).
The study may expand to Part 2 with up to 150 patients in H1 2025, focusing on motor symptoms and biomarkers for potential pivotal study transition.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment